MYND — MYND Life Sciences Balance Sheet
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual balance sheet for MYND Life Sciences, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 0 | 1.94 | 0.11 | 0.013 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0 | 0.098 | 0.128 | 0.778 |
| Total Current Assets | 0 | 2.04 | 0.239 | 0.791 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0 | 0.328 | 0.115 | 0.006 |
| Net Intangible Assets | ||||
| Long Term Investments | ||||
| Total Assets | 0 | 2.67 | 0.654 | 0.798 |
| Accounts Payable | ||||
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Current Portion of Long Term Debt / Capital Leases | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 0.054 | 0.355 | 4.13 | 5.77 |
| Long Term Debt | ||||
| Capital Lease Obligations | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Deferred Income Tax | ||||
| Total Liabilities | 0.054 | 2.74 | 4.19 | 5.77 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | -0.054 | -0.068 | -3.53 | -4.98 |
| Total Liabilities & Shareholders' Equity | 0 | 2.67 | 0.654 | 0.798 |
| Total Common Shares Outstanding |